Literature DB >> 25769547

High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia.

Mohsen Karimi1, Christer Nilsson1, Marios Dimitriou1, Monika Jansson1, Hans Matsson2, Per Unneberg3, Sören Lehmann1, Juha Kere4, Eva Hellström-Lindberg5.   

Abstract

Entities:  

Keywords:  acute myeloid leukemia; high-throughput mutational screening; myelodysplastic syndromes; secondary; therapy-related

Mesh：

Year:  2015        PMID： 25769547      PMCID： PMC4450634          DOI： 10.3324/haematol.2014.118034

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Revised international prognostic scoring system for myelodysplastic syndromes.

Authors:  Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

2.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Authors:  David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

3.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data.

Authors:  Kai Wang; Mingyao Li; Hakon Hakonarson
Journal:  Nucleic Acids Res       Date:  2010-07-03       Impact factor: 16.971

4.  Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.

Authors:  Z Y Lim; W Ingram; R Brand; A Ho; M Kenyon; S Devereux; J Marsh; G J Mufti; A Pagliuca
Journal:  Bone Marrow Transplant       Date:  2009-09-21       Impact factor: 5.483

5.  SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).

Authors:  Manja Meggendorfer; Andreas Roller; Torsten Haferlach; Christiane Eder; Frank Dicker; Vera Grossmann; Alexander Kohlmann; Tamara Alpermann; Kenichi Yoshida; Seishi Ogawa; H Phillip Koeffler; Wolfgang Kern; Claudia Haferlach; Susanne Schnittger
Journal:  Blood       Date:  2012-08-23       Impact factor: 22.113

6.  Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.

Authors:  Guillermo Garcia-Manero; Francesco Paolo Tambaro; Nebiyou B Bekele; Hui Yang; Farhad Ravandi; Elias Jabbour; Gautam Borthakur; Tapan M Kadia; Marina Y Konopleva; Stefan Faderl; Jorge E Cortes; Mark Brandt; Yumin Hu; Deborah McCue; Willie Mae Newsome; Sherry R Pierce; Marcos de Lima; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

7.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

Authors:  E Papaemmanuil; M Cazzola; J Boultwood; L Malcovati; P Vyas; D Bowen; A Pellagatti; J S Wainscoat; E Hellstrom-Lindberg; C Gambacorti-Passerini; A L Godfrey; I Rapado; A Cvejic; R Rance; C McGee; P Ellis; L J Mudie; P J Stephens; S McLaren; C E Massie; P S Tarpey; I Varela; S Nik-Zainal; H R Davies; A Shlien; D Jones; K Raine; J Hinton; A P Butler; J W Teague; E J Baxter; J Score; A Galli; M G Della Porta; E Travaglino; M Groves; S Tauro; N C Munshi; K C Anderson; A El-Naggar; A Fischer; V Mustonen; A J Warren; N C P Cross; A R Green; P A Futreal; M R Stratton; P J Campbell
Journal:  N Engl J Med       Date:  2011-09-26       Impact factor: 91.245

8.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

9.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.

Authors:  T Haferlach; Y Nagata; V Grossmann; Y Okuno; U Bacher; G Nagae; S Schnittger; M Sanada; A Kon; T Alpermann; K Yoshida; A Roller; N Nadarajah; Y Shiraishi; Y Shiozawa; K Chiba; H Tanaka; H P Koeffler; H-U Klein; M Dugas; H Aburatani; A Kohlmann; S Miyano; C Haferlach; W Kern; S Ogawa
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528

10.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113
View more
  6 in total

1.  SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells.

Authors:  Teresa Mortera-Blanco; Marios Dimitriou; Petter S Woll; Mohsen Karimi; Edda Elvarsdottir; Simona Conte; Magnus Tobiasson; Monika Jansson; Iyadh Douagi; Matahi Moarii; Leonie Saft; Elli Papaemmanuil; Sten Eirik W Jacobsen; Eva Hellström-Lindberg
Journal:  Blood       Date:  2017-06-20       Impact factor: 22.113

2.  Therapy-related myelofibrosis does not appear to exist.

Authors:  Lucia Masarova; Gabriele Todisco; Taghi Manshouri; Kate J Newberry; Jorge E Cortes; Hagop M Kantarjian; Zeev Estrov; Srdan Verstovsek
Journal:  Blood Adv       Date:  2017-05-26

3.  Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis.

Authors:  Xue Zheng; Zhi Zhan; Duolan Naren; Jing Li; Tianyou Yan; Yuping Gong
Journal:  PLoS One       Date:  2017-09-27       Impact factor: 3.240

4.  Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies.

Authors:  Sarah Bertoli; Arthur Sterin; Suzanne Tavitian; Lucie Oberic; Loïc Ysebaert; Reda Bouabdallah; François Vergez; Audrey Sarry; Emilie Bérard; Françoise Huguet; Guy Laurent; Thomas Prébet; Norbert Vey; Christian Récher
Journal:  Oncotarget       Date:  2016-12-27

5.  Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.

Authors:  Christian Scharenberg; Valentina Giai; Andrea Pellagatti; Leonie Saft; Marios Dimitriou; Monika Jansson; Martin Jädersten; Alf Grandien; Iyadh Douagi; Donna S Neuberg; Katarina LeBlanc; Jacqueline Boultwood; Mohsen Karimi; Sten Eirik W Jacobsen; Petter S Woll; Eva Hellström-Lindberg
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

Review 6.  Aberrant splicing and drug resistance in AML.

Authors:  Rosalia de Necochea-Campion; Geoffrey P Shouse; Qi Zhou; Saied Mirshahidi; Chien-Shing Chen
Journal:  J Hematol Oncol       Date:  2016-09-10       Impact factor: 17.388
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.